Celgene Corporation announced that the European Commission (EC) has approved the label expansion of IMiD medications: leading oncology drug Revlimid (lenalidomide) and Imnovid.
The EC approved Revlimid in combination with Velcade and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The approval for RVd was supported by data from SWOG S0777, a phase III trial evaluating the triplet combination, RVd, in adult patients with previously untreated multiple myeloma.
The commission also approved Imnovid in combination with Velcade and dexamethasone (PVd) for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
The approval of PVd was supported by data from OPTIMISMM study, which evaluated the regimen in patients who were previously treated with Revlimid.
An approval was in the cards as the CHMP had recommended approval of the same last month.
The new triplet regimens should improve outcomes for both newly diagnosed patients as well as those who have relapsed or become refractory to first-line therapy. Thus, sales should get a boost. Celgene's key growth driver, Revlimid, an oral immunomodulatory drug, is currently approved for several indications, including multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. Net sales of Revlimid came in at $2.6 billion in the first quarter, reflecting 15% year-over-year increase.
Celgene's stock has gained 49.1% in the year so far compared with the industry's rise of 2.4%.
Celgene has been in the news for its impending merger with Bristol-Myers Squibb Company (BMY - Free Report) . In January, Bristol-Myers had announced that it will acquire Celgene for approximately $74 billion.
The merger is expected to close in the third quarter.
The acquisition announcement prompted quite a few other deals. Another leading biotech, Biogen (BIIB - Free Report) announced that it will acquire Nightstar Therapeutics. Swiss pharma giant, Roche (RHHBY - Free Report) announced that it will acquire Spark Therapeutics for $5 billion.
Zacks Rank
Celgene currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Celgene Corporation announced that the European Commission (EC) has approved the label expansion of IMiD medications: leading oncology drug Revlimid (lenalidomide) and Imnovid.
The EC approved Revlimid in combination with Velcade and dexamethasone (RVd) for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant. The approval for RVd was supported by data from SWOG S0777, a phase III trial evaluating the triplet combination, RVd, in adult patients with previously untreated multiple myeloma.
The commission also approved Imnovid in combination with Velcade and dexamethasone (PVd) for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
The approval of PVd was supported by data from OPTIMISMM study, which evaluated the regimen in patients who were previously treated with Revlimid.
An approval was in the cards as the CHMP had recommended approval of the same last month.
The new triplet regimens should improve outcomes for both newly diagnosed patients as well as those who have relapsed or become refractory to first-line therapy. Thus, sales should get a boost. Celgene's key growth driver, Revlimid, an oral immunomodulatory drug, is currently approved for several indications, including multiple myeloma, myelodysplastic syndromes and mantle cell lymphoma. Net sales of Revlimid came in at $2.6 billion in the first quarter, reflecting 15% year-over-year increase.
Celgene's stock has gained 49.1% in the year so far compared with the industry's rise of 2.4%.
Celgene has been in the news for its impending merger with Bristol-Myers Squibb Company (BMY - Free Report) . In January, Bristol-Myers had announced that it will acquire Celgene for approximately $74 billion.
The merger is expected to close in the third quarter.
The acquisition announcement prompted quite a few other deals. Another leading biotech, Biogen (BIIB - Free Report) announced that it will acquire Nightstar Therapeutics. Swiss pharma giant, Roche (RHHBY - Free Report) announced that it will acquire Spark Therapeutics for $5 billion.
Zacks Rank
Celgene currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BIIB - FREE
Get the latest research report on RHHBY - FREE
Get the latest research report on BMY - FREE